Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages 279-286

  Gopal, Satish ^a   Patel, Monita R ^a   Achenbach, Chad J ^b   Yanik, Elizabeth L ^a   Cole, Stephen R ^a   Napravnik, Sonia ^a   Burkholder, Greer A ^c   Mathews, W Christopher ^d   Rodriguez, Benigno ^e   Deeks, Steven G ^f   Mayer, Kenneth H ^g   Moore, Richard D ^h   Kitahata, Mari M ⁱ   Richards, Kristy L ^a   Eron, Joseph J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Fenway Health   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

immune reconstitution inflammatory syndrome

Indexed keywords

VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BURKITT LYMPHOMA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HEPATITIS B; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SURVIVAL; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; COHORT ANALYSIS; COMPLICATION; INCIDENCE; SURVIVAL ANALYSIS; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; LYMPHOMA; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84903984639     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu270     Document Type: Article

References (40)

1. Lanoy E, Rosenberg PS, Fily F, et al. HIV-Associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 2011; 118:44-9.
2. Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011; 25:1395-403.
3. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013; 57:756-64.
4. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-Associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis. 2008; 8:516-23. (Pubitemid 352005824)
5. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: Proposed clinical case definitions. Lancet Infect Dis. 2010; 10:791-802.
6. Meintjes G, Scriven J, Marais S. Management of the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep. 2012; 9:238-50.
7. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: A prospective study. AIDS 2008; 22:601-10. (Pubitemid 351640593)
8. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and metaanalysis. Lancet Infect Dis. 2010; 10:251-61.
9. BowerM, Nelson M,Young AM,et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224-8. (Pubitemid 46224033)
10. Letang E, Lewis JJ, BowerM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: Higher incidence and mortality in Africa than in the UK. AIDS 2013; 27:1603-13.
11. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis. 2012; 54:424-33.
12. Kitahata MM, Rodriguez B, Haubrich R, et al. Cohort profile: The Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 2008; 37:948-55.
13. Achenbach CJ, Cole SR, Kitahata MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011; 25:691-700.
14. HaddowLJ, EasterbrookPJ,MosamA, et al.Definingimmunereconstitution inflammatory syndrome: Evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis. 2009; 49:1424-32.
15. Cole SR, Hudgens MG. Survival analysis in infectious disease research: Describing events in time. AIDS 2010; 24:2423-31.
16. Dunleavy K, Wilson WH. How I treat HIV-Associated lymphoma. Blood 2012; 119:3245-55.
17. Bohlius J, Schmidlin K, Boue F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: Incidence and evolution of CD4(+) T-cell lymphocytes. Blood 2011; 117:6100-8.
18. Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: What do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010; 116:5600-4.
19. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/ AIDS. Blood 2006; 108:3786-91. (Pubitemid 44864560)
20. Morton LM, Kim CJ, Weiss LM, et al. Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and-uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era. Leuk Lymphoma 2014; 55:551-7.
21. Chao C, Silverberg MJ, Martinez-Maza O, et al. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma. Clin Cancer Res 2012; 18:4702-12.
22. Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-Associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011; 20:1303-14.
23. Liapis K, Clear A, Owen A, et al. The microenvironment of AIDSrelated diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 2013; 122:424-33.
24. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: Epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117:1792-8.
25. Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-Associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 2013; 105:1221-9.
26. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-Associated tuberculous meningitis. Clin Infect Dis. 2011; 52:1374-83.
27. Longley N, Harrison TS, Jarvis JN. Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis. 2013; 26:26-34.
28. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective cohort study. PLoS Med 2010; 7:e1000384.
29. Noy A. Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol 2010; 22:443-8.
30. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-Associated Burkitt's lymphoma. AIDS 2010; 24: 851-6.
31. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64.
32. Riley JL. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 2013; 369:187-9.
33. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-Associated malignancies. Clin Cancer Res 2013; 19:3462-73.
34. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
35. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54.
36. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16. (Pubitemid 29318842)
37. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis. 1999; 180:1050-6. (Pubitemid 30070186)
38. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6. (Pubitemid 27450659)
39. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998; 178:70-9. (Pubitemid 28328078)
40. Antonelli LR, Mahnke Y, Hodge JN, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010; 116: 3818-27.